In a phase 3 study for infantile-onset Pompe disease, Nexviazyme from Sanofi successfully achieved all primary and secondary objectives. This signifies a significant milestone in the treatment of the disease, which impacts an estimated X number of individuals worldwide. The positive outcomes of the study suggest promising prospects for individuals diagnosed with infantile-onset Pompe disease, who currently face limited treatment options. The success of Nexviazyme in meeting all endpoints highlights its potential to offer improved care and outcomes for patients suffering from this rare genetic disorder.